Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03792139Phase 1Completed
Phase 1, open-label trial of ly3200882 in cancer, pancreatic cancer (PC) and glioma (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Drug Concentration of LY3200882 and Area Under the Concentration Curve of LY3200882. Started Jan 2019; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03792139.